A decision-ready blueprint
A licensing and commercialisation solution designed around the commercial realities of academic technology transfer offices and research centers.
Scientific, commercial, and digital architecture, with specialist expertise assembled where the engagement requires it.
Academic medical and translational centres need a disciplined route from promising research and institutional capability to a licensing or out-licensing decision that can withstand scientific, IP, commercial, and institutional review. The challenge is not simply identifying more opportunities. It is making the evidence, value proposition, partner logic, and approval pathway clear enough to support responsible external engagement.
Lonrú Consulting designs the licensing solution around that work. We help technology-transfer teams and institutional stakeholders establish an evidence-led view of the selected opportunity, test the commercial questions that matter, and prepare controlled materials for the next licensing, partner, or portfolio decision.
We define the approved research, IP, translational, regulatory, market, partner, and institutional inputs relevant to the selected licensing question, including ownership, permissions, and publication boundaries.
Configured systems can structure approved evidence, prepare comparative analysis, identify defined information gaps, or assemble review-ready opportunity material within the agreed controls.
Lonrú provides principal-led commercial strategy, licensing framing, and review governance. Research leads, technology-transfer professionals, institutional decision-makers, and client-selected specialists review work within their areas of accountability.
Approved outputs are delivered through an opportunity view, evidence map, licensing dossier, partner workspace, or portfolio interface suited to the next institutional decision.
Relate the approved science, IP position, translational status, market context, and development questions behind a selected opportunity without overstating its readiness or value.
Bring relevant partner, therapeutic-area, market, and capability signals into a structured assessment that helps the institution focus external engagement.
Organise approved research, technical, IP, and commercial material into a review-ready dossier or workspace while keeping confidential information within agreed boundaries.
Give technology-transfer and institutional leaders a usable view of the selected opportunities, evidence gaps, review needs, and next actions that require attention.
The work can structure evidence, assess agreed commercial questions, and prepare material for review. It does not make an unapproved valuation, licensing, investment, legal, or institutional decision on behalf of the client.
Research ownership, IP permissions, publication requirements, and external-sharing authority are established at the outset. Final approval remains with the appropriate institutional, research, legal, and technology-transfer owners.
Relevant experience
Scenario modelling
Designed Algorithmic Asset Viability Scanners that model strategic biotech out-licensing and spin-out scenarios, integrating clinical trial attrition probabilities, IP valuation, and regulatory hurdles to support rapid investment screening.
Audit-ready
Formulated Technical Dossier Authoring frameworks that automate ingestion and structure of preclinical data pipelines for FDA IND and BLA submissions, producing organized, audit-ready regulatory dossiers.
Architecture in context
Diagram summary: Research, IP, translational, market, partner, and institutional review inputs are contextualised, analysed, and tested through ActiveArchitecture™ before they support a licensing or out-licensing decision.
Practical questions
Next step
Bring the decision, workflow, or delivery constraint that needs a clearer operating path.
Request a focused briefingLicensing questions we help clarify
A focused workstream creates a clearer basis for external engagement by bringing the right questions into view before an opportunity is shared.